Skip to main content

Table 2 Patient’s demographics according to cardiac 18F-FDG uptake

From: Clinical significance of visual cardiac 18F-FDG uptake in advanced non-small cell lung cancer

Different variables

Total

cardiac 18F-FDG by SUVmax

n = 43

High (n = 22)

Low (n = 21)

p-value

Age

 < 70 yr / ≥ 70 yr

17 / 26

8 / 14

9 / 12

0.663

Gender

Male / Female

29 / 14

14 / 8

15 / 6

0.586

ECOG PS

0–1 / 2–3

38 / 4

21/1

17 / 3

0.249

Smoking

Yes / No

34 / 9

15 / 7

19 / 2

0.072

Histology

AC / Non-AC

30 / 13

18 / 4

12 / 9

0.078

Stage

Non-IV / IV

2 / 41

1 / 21

1 / 20

0.973

NLR

High / Low

22 / 21

8 / 14

14 / 7

0.047

PLR

High / Low

22 / 21

10 / 12

12 / 9

0.443

PNI

High / Low

22 / 21

13 / 9

9 / 12

0.287

GPS

0 / 1–2

25 / 18

15 / 7

10 / 11

0.172

BMI

High / Low

27 / 16

15 / 7

12 / 9

0.454

Cachexia

Yes / No

17 / 26

6 / 16

11 / 10

0.092

Weight loss

Yes / No

15 / 21

5 / 13

10 / 8

0.091

Tumor SUVmax

High / Low

21 / 21

10 / 11

11 / 10

0.758

Tumor MTV

High / Low

19 / 19

6 / 14

13 / 5

0.009

Tumor TLG

High / Low

19 / 19

6 / 14

13 / 5

0.009

  1. Abbreviations: SUVmax, the maximum of standardized uptake value, MTV Metabolic tumor volume, TLG Total lesion glycolysis, ECOG PS Eastern cooperative oncology group performance status, AC Adenocarcinoma; non-AC, non-adenocarcinoma, CRP C-reactive protein, PD-L1 Programmed death ligand-1, NLR Neutrophil to lymphocyte ratio, PLR Platelet to lymphocyte ratio, SII Systemic immune inflammation index, PNI Prognostic nutrition index, ALI Advanced lung cancer inflammation index, GPS Glasgow prognostic score, BMI Body mass index
Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us